© 2016, Bayer AS
Siste oppdatering 08 april 2016
L.NO.MKT.03.2016.1478

For the Press

The Press Resources page is designed to give you online access to timely and relevant information about Xarelto®. In this section you will find information and resources for journalists, including current and archived press releases as well as a collection of background information and images related to Xarelto®.


About Xarelto®

Xarelto® is indicated for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.1

Xarelto® belongs to a group of medicines called anticoagulants. It works by blocking the blood clotting Factor Xa and thereby reduces the tendency of the blood to form clots.1

Venous blood clots originate in the blood vessels that transport the blood back into the heart and from there to the lungs. Venous thromboembolism (VTE) can take the form of either a deep vein thrombosis (DVT), a blood clot in a deep vein (usually in the leg), or a pulmonary embolism (PE), a potentially life-threatening blood clot blocking a vessel in the lungs.14
  • A deep vein thrombosis (DVT) is a blood clot in a deep vein (usually in the leg) that partially or totally blocks the flow of blood.
  • A pulmonary embolism (PE) is a blood clot which breaks off and travels through the body, ultimately blocking a blood vessel in the lungs.


Healthy patients undergoing elective major orthopaedic surgery, such as total knee or total hip replacement, are at risk of venous blood clots due to factors such as vascular damage and reduced mobility.43 Venous blood clots occur in 40-60% of patients undergoing orthopaedic surgery who do not receive preventive care.61, 65

Recent guidelines recommend the routine use of anticoagulants for patients undergoing elective hip or knee replacement surgery.6

Fast Facts

  • The extensive clinical trial programme for Xarelto® covering acute and chronic indications makes it the most studied oral, direct Factor Xa inhibitor in the world today. Almost 50,000 patients are expected to be enrolled overall in the Xarelto® clinical development program.9
  • Venous blood clots kill more people in Europe each year than AIDS, breast cancer, prostate cancer, and road traffic accidents combined.46, 47
  • VTE causes over 500,000 deaths in Europe every year.46
  • An estimated 300,000 VTE-related deaths occur in the US each year.41
  • Almost all the hospital deaths resulting from PE are preventable.59

Background information

  • 1 - Xarelto® (rivaroxaban) Summary of Product Characteristics as approved by the European Commission.
  • 14 - Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325(7369):887-890.
  • 43 - Merli GJ. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. Clin Geriatr Med. 2006;22(1):75-92.
  • 61 - Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S-400S.
  • 65 - White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455.
  • 6 - Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
  • 9 - International Congress on Thrombosis: Rivaroxaban is first novel oral anticoagulant to significantly reduce the composite outcome of symptomatic VTE and death [press release]. Leverkusen, Germany: Bayer HealthCare AG; June 30, 2008.
  • 46 - Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-764.
  • 47 - Fitzmaurice DA, Murray E. Thromboprophylaxis for adults in hospital. BMJ. 2007;334(7602):1017-1018.
  • 41 - Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611-1617.
  • 59 - House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. Available at http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99.pdf
Factor Xa
Pivotal component of blood clotting cascade. Stimulates the production of thrombin, the enzyme in the coagulation cascade that promotes the formation of blood clots.
Major orthopaedic surgery
Major operations on the bones or joints including total hip or knee replacement surgery.
Thrombosis
Formation of a clot inside a blood vessel.
Venous thromboembolism
A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.
Pulmonary embolism
A potentially fatal condition caused by a blood clot blocking a vessel in the lung: usually the clot originates from a DVT in the legs. PE can result in permanent lung damage.

Press Releases

19th Mar 2009

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:

U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer’s rivaroxaban

08. Dec 2008

Venous Blood Clot Prevention after Knee or Hip Replacement Surgery:

Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program

Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto

RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show Clinical Benefit in Head-to-Head Comparison Against U.S.-Approved Regimen of Enoxaparin

10. Nov 2008

Secondary Prevention in Acute Coronary Syndrome (ACS):

Bayer’s Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome

Phase II Data Presented as Late-Breaker at American Heart Association Meeting

Phase III Study to be Initiated in December 2008

01. Oct 2008

Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:

Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU

Bayer will start marketing the new oral, once-daily anticoagulant very soon

First-in-class product to demonstrate superior efficacy to current standard of care

16 Sept 2008

Venous Blood Clot Prevention after Elective Total Knee and Hip Replacement Surgery:

Bayer’s Xarelto® Approved in Canada

First approval for Bayer's new oral, once-daily anticoagulant

Marketing to start immediately

First-in-class product to demonstrate superior efficacy to standard of care

Most studied oral, direct Factor Xa inhibitor in the world today

31 Aug 2008

Secondary prevention in acute coronary syndrome (ACS):

Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November 2008

First data presentation from large dose-finding trial involving about 3,500 patients

Acceleration of clinical development in acute coronary syndrome planned

30 Jul 2008

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:

Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.

Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily

No evidence of safety issues attributable to rivaroxaban after long-term exposure

25 Jul 2008

Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:

Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU

Final approval from the European Commission expected within the next few months

30 Jun 2008

Venous Blood Clot Prevention after Knee and Hip Replacement Surgery:

Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death

Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a

Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly

26. Jun 2008

Venous Blood Clot Prevention after Total Hip and Knee Replacement Surgery:

New England Journal of Medicine Publishes Results from Two of the Landmark Phase III RECORD Studies with Rivaroxaban

Head-to-Head trials involving over 7000 patients after Major Orthopedic Surgery

Rivaroxaban superior to Enoxaparin in Preventing Venous Blood Clots

Bleeding rates were low and comparable between the treatment arms

25. Jun 2008

Venous Blood Clot Prevention after Hip Replacement Surgery:

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

Trial involving over 2.500 patients after hip replacement surgery

Five weeks of Rivaroxaban compared to two weeks enoxaparin

Extended Rivaroxaban treatment regimen significantly more effective with comparable low bleeding rates

30. May 2008

Prevention of Thromboembolism after Knee Replacement Surgery:

Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial

Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice- Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates

RECORD4 Confirms Results of RECORD1, 2 and 3

U.S. Submission Planned for mid 2008

Prof. Turpie: “Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots”

10. Dec 2007

VTE Prevention After Major Orthopaedic Surgery:

Three Pivotal Phase III Trials Show Superior Efficacy of Rivaroxaban over Standard of Care with Enoxaparin

Consistent results across three RECORD trials involving nearly 10,000 patients

Venous thromboembolism considered the most frequent and potentially fatal complication following major orthopaedic surgery

No evidence of liver signal attributable to rivaroxaban has been seen

8. Dec 2007

VTE Prevention After Hip Replacement Surgery:

Pivotal Phase III Data Show Superior Efficacy of Rivaroxaban over Enoxaparin

Head-to-Head Study Demonstrates Similar and Low Rate of Bleeding for Both Drugs

9. Nov 2007
31. Oct 2007

Prevention of Venous Thromboembolism after Major Orthopedic Surgery:

Bayer HealthCare Submits Rivaroxaban for European Approval

Data Package for Rivaroxaban Involves Nearly 10,000 Patients in Three Phase III Trials


Images

Xarelto in Factor Xa Molecule

Image shows one molecule of Xarelto blocking the active site of a Factor Xa protein (generated from X-ray crystallography).

www.xarelto.com ©2008, Bayer Schering Pharma AG



Propagation

Activated Factor X, functioning as part of the prothrombinase complex on the surface of activated platelets, converts large amounts of prothrombin to thrombin, in the “thrombin burst.”







Embolus formation

Fragments of thrombi can break free to form potentially life-threatening pulmonary emboli.









Pulmonary embolus

Whole lung in which pulmonary arteries are obstructed by fresh (red) thrombus (circles).









Pulmonary embolism

The pathway of a pulmonary embolism (PE) from the lower half of the body: inferior vena cava, to right atrium, to right ventricle, to the pulmonary artery. This eventually obstructs blood flow to the lung. Patients with deep vein thrombosis (DVT) are at risk of PE, a life-threatening event.



Major veins of the lower extremity

The most common type of VTE is deep vein thrombosis (DVT), which occurs in veins deep within the muscles of the leg and pelvis.


















Kontakt oss

Alexander Siedler

Global R&D and Scientific Communication

Address:

Bayer Schering Pharma AG Germany-13342 Berlin

Telephone: +49 30 468 12727
Fax: +49 30 468 16710

E-post Alexander Siedler

Jeg er ikke helsepersonell

Find out more about Xarelto

Go to Patient Page

Viste du?

1 of 9 View all facts

The overall Xarelto® study programme is planned to include about 50,000 patients. To date, rivaroxaban is the most studied oral direct Factor Xa inhibitor in development. 9

Foregående fakta Neste fakta